These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 19283354)

  • 1. Delivery of high levels of anti-proliferative nucleoside triphosphates to CYP3A-expressing cells as a potential treatment for hepatocellular carcinoma.
    MacKenna DA; Montag A; Boyer SH; Linemeyer DL; Erion MD
    Cancer Chemother Pharmacol; 2009 Oct; 64(5):981-91. PubMed ID: 19283354
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and characterization of a novel liver-targeted prodrug of cytosine-1-beta-D-arabinofuranoside monophosphate for the treatment of hepatocellular carcinoma.
    Boyer SH; Sun Z; Jiang H; Esterbrook J; Gómez-Galeno JE; Craigo W; Reddy KR; Ugarkar BG; MacKenna DA; Erion MD
    J Med Chem; 2006 Dec; 49(26):7711-20. PubMed ID: 17181153
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rabbit cytochrome P450 4B1: A novel prodrug activating gene for pharmacogene therapy of hepatocellular carcinoma.
    Mohr L; Rainov NG; Mohr UG; Wands JR
    Cancer Gene Ther; 2000 Jul; 7(7):1008-14. PubMed ID: 10917203
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined use of chemotherapeutics and oncolytic adenovirus in treatment of AFP-expressing hepatocellular carcinoma.
    Mao CY; Hua HJ; Chen P; Yu DC; Cao J; Teng LS
    Hepatobiliary Pancreat Dis Int; 2009 Jun; 8(3):282-7. PubMed ID: 19502169
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of fucoidan on the biotinidase kinetics in human hepatocellular carcinoma.
    Hayakawa K; Nagamine T
    Anticancer Res; 2009 Apr; 29(4):1211-7. PubMed ID: 19414366
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liver-targeted drug delivery using HepDirect prodrugs.
    Erion MD; van Poelje PD; Mackenna DA; Colby TJ; Montag AC; Fujitaki JM; Linemeyer DL; Bullough DA
    J Pharmacol Exp Ther; 2005 Feb; 312(2):554-60. PubMed ID: 15340017
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of cytarabine prodrugs and delivery systems for leukemia treatment.
    Chhikara BS; Parang K
    Expert Opin Drug Deliv; 2010 Dec; 7(12):1399-414. PubMed ID: 20964588
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systemic therapies in hepatocellular carcinoma.
    Wörns MA; Weinmann A; Schuchmann M; Galle PR
    Dig Dis; 2009; 27(2):175-88. PubMed ID: 19546557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipophilic arabinofuranosyl cytosine derivatives in liposomes.
    Schwendener R; Schott H
    Methods Enzymol; 2005; 391():58-70. PubMed ID: 15721374
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis, and characterization of a series of cytochrome P(450) 3A-activated prodrugs (HepDirect prodrugs) useful for targeting phosph(on)ate-based drugs to the liver.
    Erion MD; Reddy KR; Boyer SH; Matelich MC; Gomez-Galeno J; Lemus RH; Ugarkar BG; Colby TJ; Schanzer J; Van Poelje PD
    J Am Chem Soc; 2004 Apr; 126(16):5154-63. PubMed ID: 15099098
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Two novel nucleoside ester derivatives of chlorambucil as potential antileukemic prodrugs: a preliminary study.
    Kryczka T; Kazimierczuk Z; Kozłowska M; Chrapusta SJ; Vilpo L; Vilpo J; Stachnik K; Janisz M; Grieb P
    Anticancer Drugs; 2007 Mar; 18(3):301-10. PubMed ID: 17264763
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liver cancer stem cells: implications for a new therapeutic target.
    Lee TK; Castilho A; Ma S; Ng IO
    Liver Int; 2009 Aug; 29(7):955-65. PubMed ID: 19490415
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer.
    Ramanathan RK; Belani CP; Singh DA; Tanaka M; Lenz HJ; Yen Y; Kindler HL; Iqbal S; Longmate J; Mack PC; Lurje G; Gandour-Edwards R; Dancey J; Gandara DR
    Cancer Chemother Pharmacol; 2009 Sep; 64(4):777-83. PubMed ID: 19169683
    [TBL] [Abstract][Full Text] [Related]  

  • 14. mTOR inhibitors for hepatocellular cancer: a forward-moving target.
    Treiber G
    Expert Rev Anticancer Ther; 2009 Feb; 9(2):247-61. PubMed ID: 19192962
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel modified steroid derivatives of androstanolone as chemotherapeutic anti-cancer agents.
    El-Far M; Elmegeed GA; Eskander EF; Rady HM; Tantawy MA
    Eur J Med Chem; 2009 Oct; 44(10):3936-46. PubMed ID: 19447526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiblastic drug targeting to hepatocellular carcinoma cells: a potential therapeutic improvement?
    Merle P; Trepo C
    Ital J Gastroenterol Hepatol; 1998 Apr; 30(2):178-80. PubMed ID: 9675654
    [No Abstract]   [Full Text] [Related]  

  • 17. Inhibitory effects of ganoderma lucidum on tumorigenesis and metastasis of human hepatoma cells in cells and animal models.
    Weng CJ; Chau CF; Yen GC; Liao JW; Chen DH; Chen KD
    J Agric Food Chem; 2009 Jun; 57(11):5049-57. PubMed ID: 19422227
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of xenobiotic and steroid hormone metabolizing enzymes in hepatocellular tumors of the non-cirrhotic liver.
    Haas S; Merkelbach-Bruse S; Justenhoven C; Brauch H; Fischer HP
    Pathol Res Pract; 2009; 205(10):716-25. PubMed ID: 19596526
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of fludarabine in hematological malignancies.
    Montillo M; Ricci F; Tedeschi A
    Expert Rev Anticancer Ther; 2006 Sep; 6(9):1141-61. PubMed ID: 17020450
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long intracellular retention of 4'-thio-arabinofuranosylcytosine 5'-triphosphate as a critical factor for the anti-solid tumor activity of 4'-thio-arabinofuranosylcytosine.
    Someya H; Waud WR; Parker WB
    Cancer Chemother Pharmacol; 2006 Jun; 57(6):772-80. PubMed ID: 16180016
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.